Changes in HbA1c level over a 12-week follow-up in patients with type 2 diabetes following a medication change

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Hirst, Jennifer A ^a   Stevens, Richard J ^a   Farmer, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; RECEIVER OPERATING CHARACTERISTIC; UNITED KINGDOM; ANALYSIS; BLOOD; BLOOD GLUCOSE MONITORING; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDY; TIME;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 84899816292     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092458     Document Type: Article

References (24)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, et al. (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378: 31-40.
2. Kanavos P, van den Aardweg S, W S (2012) Diabetes expenditure, burden of disease and management in 5 EU countries. LSE Health, London School of Economics.
3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, et al. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405-412. (Pubitemid 30609442)
4. NICE (2008) Type 2 diabetes: National clinical guideline for management in primary and secondary care (update). NICE clinical guideline 66: Royal College of Physicians.
5. ADA (2013) Standards of medical care in diabetes-2013. Diabetes Care 36: S11-66.
6. Kilpatrick ES (2008) Haemoglobin A1c in the diagnosis and monitoring of diabetes mellitus. J Clin Pathol 61: 977-982.
7. Bunn HF, Haney DN, Kamin S, Gabbay KH, Gallop PM (1976) The biosynthesis of human hemoglobin A1c. Slow glycosylation of hemoglobin in vivo. J Clin Invest 57: 1652-1659.
8. Mortensen HB, Christophersen C (1983) Glucosylation of human haemoglobin a in red blood cells studied in vitro. Kinetics of the formation and dissociation of haemoglobin A1c. Clin Chim Acta 134: 317-326. (Pubitemid 13017371)
9. Osterman-Golkar SM, Vesper HW (2006) Assessment of the relationship between glucose and A1c using kinetic modeling. J Diabetes Complications 20: 285-294. (Pubitemid 44292530)
10. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, et al. (2011) Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 57: e1-e47.
11. Tahara Y, Shima K (1993) The response of GHb to stepwise plasma glucose change over time in diabetic patients. Diabetes Care 16: 1313-1314. (Pubitemid 23259881)
12. Tahara Y, Shima K (1995) Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 18: 440-447.
13. Kennedy L, Herman WH, Strange P, Harris A (2006) Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care 29: 1-8. (Pubitemid 44033422)
14. Salvagno GL, Lippi G, Targher G, Montagnana M, Guidi GC (2007) Monitoring glycaemic control: is there evidence for appropriate use of routine measurement of glycated haemoglobin? Clin Chem Lab Med 45: 1065-1067. (Pubitemid 47424860)
15. Bosi E, Dotta F, Jia Y, Goodman M (2009) Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 11: 506-515.
16. Loh TP, Tan KM, Saw S, Sethi SK (2011) Glycated haemoglobin: what is the diagnostic yield at shortened testing intervals? Diabetes Res Clin Pract 94: e40-42.
17. Driskell OJ, Holland D, Hanna FW, Jones PW, Pemberton RJ, et al. (2012) Inappropriate requesting of glycated hemoglobin (Hb A1c) is widespread: assessment of prevalence, impact of national guidance, and practice-to-practice variability. Clin Chem 58: 906-915.
18. Lyon AW, Higgins T, Wesenberg JC, Tran DV, Cembrowski GS (2009) Variation in the frequency of hemoglobin A1c (HbA1c) testing: population studies used to assess compliance with clinical practice guidelines and use of HbA1c to screen for diabetes. J Diabetes Sci Technol 3: 411-417.
19. Akan P, Cimrin D, Ormen M, Kume T, Ozkaya A, et al. (2007) The inappropriate use of HbA1c testing to monitor glycemia: is there evidence in laboratory data? J Eval Clin Pract 13: 21-24. (Pubitemid 46238792)
20. NGSP (2014) List of NGSP Certified Methods.
21. Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008) Predictive Validity of a Medication Adherence Measure in an Outpatient Setting. The Journal of Clinical Hypertension 10: 348-354.
22. Muntner P, Levitan EB, Joyce C, Holt E, Mann D, et al. (2013) Association Between Antihypertensive Medication Adherence and Visit-to-Visit Variability of Blood Pressure. The Journal of Clinical Hypertension 15: 112-117.
23. Berard L, Canadian Diabetes Association Clinical Practice Guidelines Expert Committee (2013) Monitoring Glycemic Control. Canadian Journal of Diabetes 37: S35-S39.
24. Tanis SP, Parker TT, Colca JR, Fisher RM, Kletzein RF (1996) Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone. J Med Chem 39: 5053-5063. (Pubitemid 27008952)